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Abstract:  
The intense accumulation of PSMA radioligands in salivary glands is still not well 
understood. It is of concern for therapeutic applications of PSMA radioligands, as 
therapeutic radiation will damage these glands. A better understanding of the uptake 
mechanism is, therefore, crucial to allow the finding of solutions to reduce toxicity. The aim 
of this study was to investigate on whether or not the accumulation of PSMA-targeting 
radioligands in submandibular glands (SMG) can be explained with PSMA expression levels 
using the methods of autoradiography (ARG) and immunohistochemistry (IHC). 
Methods: All patients gave written informed consent for further utility of the biological 
material. SMG of 9 patients, pancreatic tissue of 4 patients and prostate cancer (PCA) 
lesions of 9 patients were analyzed. Fresh tissue specimen were analyzed by means of 
PSMA-IHC (using an anti-PSMA-antibody and an immunoreactivity score system - IRS) and 
ARG using 177Lu-PSMA-617 (with quantification of the relative signal intensity compared to 
a PSMA-positive standard). The SUVmax in salivary glands, pancreas and PCA tissues were 
quantified in 60 clinical 68Ga-PSMA-11 PET scans for recurrent disease, as well as the 9 
primary tumors selected for ARG and IHC. 
Results:  
PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS 70–300) 
as well as in ARG (1.33 – 21.98%). This variability on PCA tissue could also be observed in 
68Ga-PSMA-11 PET (SUVmax 4.4-16) with a significant correlation between ARG and 
SUVmax (p < 0.001, R2 = 0.897). On IHC, ARG and 68Ga-PSMA-11 PET, the pancreatic 
tissue was negative (IRS = 0, ARG = 0.1±0.05%, SUVmax of 3.1±1.1). The SMG tissue 
displayed only focal expression of PSMA limited to the intercalated ducts on IHC (IRS 10-
15) and a minimal signal on ARG (1.3±0.9%). In contrast, all SMG showed a high 68Ga-
PSMA-11 accumulation on PET scans (SUVmax 23.5±5.2).  
Conclusions: 
Our results indicate that the high accumulation of PSMA radioligands in salivary glands 
does not correspond to a high PSMA expression levels determined using ARG and IHC. 
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These findings provide evidence, that the significant accumulation of PSMA radioligands in 
SMG is not primarily a result of PSMA-mediated uptake.  
 
 
Key words (MESH-keywords): Prostate cancer, Prostate-Specific Membrane Antigen, 
177Lu-PSMA-617, 68Ga-PSMA-11, Positron Emission Tomography, immuno-histochemistry, 
autoradiography   
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INTRODUCTION:  
The prostate-specific membrane antigen (PSMA) is upregulated in prostate cancer  
(PCA), while only a few normal organs and tissue show physiologically expression (1-3). 
Currently, 68Ga-PSMA-11 is widely used as a primary imaging tool for PCA restaging 
using positron emission tomography (PET) at biochemical recurrence (4,5). It enables 
for a high detection rate of small soft-tissue and bone lesions even at low prostate 
specific antigen (PSA) values (6). The high and specific tumor uptake of 68Ga-PSMA-11 
prompted researchers to develop PSMA-ligands with a DOTA-chelator (e.g. PSMA-617), 
for labeling with 177Lu for therapeutic applications (7,8). Off-target uptake of PSMA 
radioligands was commonly detected in kidneys, the duodenum and small bowel, as well 
as in the lacrimal and major salivary glands (9). First dosimetry studies of 177Lu-PSMA-
617 revealed a significantly higher mean absorbed dose in salivary glands (1.4 Gy/GBq) 
compared to kidney-doses (0.75 Gy/GBq) (10). This is in concordance with first results 
obtained after 177Lu-PSMA-617 therapy, where no early nephrotoxicity, but some 
transient xerostomia in  8-20%  patients was observed (7,11). High salivary gland uptake 
is of particular concern when PSMA-ligands are applied with α-particle emitters, such as 
225Ac,  since this resulted in irreversible xerostomia and, hence, dose-limiting toxicity 
(12,13). 
It was previously reported that PSMA is physiologically expressed on normal prostate 
epithelial cells, in the small intestine, renal tubular cells and the salivary glands, 
however, at much lower levels than in prostate cancer tissue (13-15). Other publications 
reported on immunohistochemical investigations which showed no PSMA expression in 
salivary glands (2,16,17).  These findings were in agreement with the fact that PSMA-
specific radioimmunoconjugates, such as 111In-J591 and 177Lu-J591, did not accumulate 
in salivary glands (18).  
A previous comment on the importance of salivary gland toxicity in PSMA targeted 
radionuclide therapy stated the lack of sufficient data and understanding of the high 
uptake of PSMA-ligands (19). 
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Published mouse-experiments do not reveal high accumulation of PSMA-targeting 
radioligands in salivary gland tissue (20,21). Therefore, such models are not suitable to 
investigate radiotherapy related side effects to the salivary glands or methods to reduce 
salivary glands uptake of PSMA-targeting ligands.  
The aim of this study was to compare the in vivo accumulation of 68Ga-PSMA-11 in 
prostate cancer tissue, salivary glands and pancreas of patients to the PSMA expression 
levels on PCA patient tissue, as well as to benign salivary gland and pancreatic tissue 
using IHC and in vitro ARG.  
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MATERIALS AND METHODS  
 
Patients for immunohistochemistry and autoradiography 
Patients undergoing neck dissections including tumor-free submandibular glands  (SMG) 
were prospectively selected. Tissue of patients that underwent pancreas resection were 
included for the analysis of benign pancreatic tissue. All patients with prostatectomy for 
PCA and preoperative 68Ga-PSMA-11 PET/MRI available were screened, and cases with 
tumor in the apex were selected, as fresh frozen tissue after standard prostatectomy was 
only available from the apex. For PET quantification in normal tissue, patients referred to a 
68Ga-PSMA-11 PET for biochemical recurrence, were selected. All patients gave written 
informed consent to further analysis of their data and biological material within biobank 
protocols approved by the local ethics committee (BASEC No. 2016-00778, 2017-01319, 
KEK-StV-Nr: 40/08 and KEK-ZH-Nr. 06/08). The direct comparison to 68Ga-PSMA-11 PET 
images was only possible for the PCA specimens. In order to determine the uptake of 68Ga-
PSMA-11  in prostate cancer relative to the uptake in salivary glands and pancreas an 
additional cohort of 60 patients that previously underwent a 68Ga-PSMA-11 PET for 
biochemical recurrence was included in a retrospective analysis (Figure 1).  
 
Tissue preparation, PSMA immunohistochemistry and evaluation 
Fresh tissue of all types, obtained from the resection specimens immediately after 
surgery, was snap frozen. The remaining tissue was formalin-fixed, paraffin-embedded 
(FFPE) and examined on 2 µm-thick hematoxylin & eosin (H&E) stained sections. Both 
tissue types were compared microscopically to be representative. Immunohistochemical 
staining for PSMA was performed according to the protocol in the supplemental data. 
PSMA expression was evaluated using a three-tiered system (1+ weak, 2+ moderate, 3+ 
strong) and the area covered by staining was estimated. Immunoreactivity score (IRS) 
was calculated as following: IRS = IHC expression score multiplied by the area covered 
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(22). The area fraction and Gleason scores were determined according to the protocol in 
the supplemental data.  
 
In vitro PSMA autoradiography 
PSMA-617 (ABX GmbH, Germany) was labeled with no-carrier added 177Lu (ITG GmbH, 
Germany) under standard labeling conditions as previously reported (supplemental data) 
(20). In vitro autoradiography was performed on frozen sections of patient tissue  and 
mouse xenografts (highly PSMA-positive PC-3 PIP and PSMA-negative PC-3 flu 
tumors;supplemental data). In brief, buffer-treated sections were incubated with a solution 
of 177Lu-PSMA-617 (1.5 MBq/mL in Tris-HCl buffer containing 1% BSA) with or without 
blocking agent (200 μM 2-(Phosphonomethyl)-pentandioic acid (2-PMPA, Sigma, USA) for 
60 min at room temperature. After removal of the radioligand solution, the sections were 
washed according to the protocol (supplemental data). The air-dried sections were exposed 
to a phosphor imaging screen (Super Resolution, Perkin Elmer, USA) that were developed 
using a radiometric phosphor imager (Cyclone Plus Storage Phosphor System, Perkin 
Elmer, USA). The signal intensity on the autoradiographic images was quantified using the 
OptiQuant Acquisition software (Version 5.0, Perkin Elmer, USA). PC-3 PIP and PC-3 flu 
tumor xenograft sections were used as a positive or negative control, respectively. It is 
important to recognize that PSMA-transduced PC-3 (PC-3 PIP) tumors express PSMA 
reproducibly at levels much higher than pathophysiological PSMA-expression levels on 
human prostate cancer (23). The percentage signal intensity relative to the PC-3 PIP 
section (set to 100%) was calculated. The images were arranged for visual display using 
Adobe Photoshop (Version CS6, Adobe Systems, USA). 
 
68Ga-PSMA-11 PET/MRI  
The nine patients with primary prostate cancer with corresponding tissue analysis 
underwent a 68Ga-PSMA-11 PET for staging high risk prostate cancer between June 2016 
and August 2017. For the second cohort of patients for PSMA PET image quantification 60 
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consequtive patients referred for 68Ga-PSMA-11 PET for biochemical recurrence were 
selected. All patients underwent a clinical routine whole-body PET/MRI 60 min after 
injection of 68Ga-PSMA-11 using a hybrid scanner (SIGNA PET/MR, GE Healthcare, 
Waukesha, WI, USA) as reported previously and described in detail in the supplements 
(24). To quantify 68Ga-PSMA-11 uptake, a standardized volume of interest (VOI) was 
positioned in regular tissue of the parotid, submandibular, lacrimal, sublingual glands, as 
well as pancreatic, hepatic and splenic tissue to assess the maximum and mean 
standardized uptake value (SUVmax and SUVmean). For patients with PSMA-positive local 
recurrence or metastasis a VOI was placed over the most active lesion.  
To quantify PSMA uptake on 68Ga-PSMA-11 PET images in the 9 primary tumors, VOIs 
were placed into the apical quadrant positive for cancer on histopathology that was selected 
for further ARG and IHC analysis.  
 
Statistical analysis 
Statistical analysis was performed with SPSS® 25.0.0.0 software (IBM®, Armonk, NY, 
USA). Descriptive statistics was used to display patient data as median, standard deviation 
(SD), or number (percent). The average activity or intensity on IHC, ARG and PET imaging 
was correlated with the values obtained for SMG, pancreas and PCA using Pearson 
correlation. A P-value lower than 0.05 was considered to indicate statistical significance.  
Linear regression was used between the signal intensity on ARG and the uptake on PSMA 
PET to estimate the relation between PSMA expression and tracer uptake on 68Ga-PSMA-
11 PET images.  
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RESULTS 
 
Patient samples for analysis of PSMA expression on SMG were isolated from 9 consecutive 
patients, for pancreatic tissue from 4 patients and for PCA tissue from 9 patients with 
cancer in the apex. In 60 patients undergoing 68Ga-PSMA-11 PET for restaging, the activity 
accumulation was determined in the lacrimal, parotid, submandibular and sublingual gland, 
as well as in pancreatic, splenic, hepatic tissue and in PCA lesions (Fig. 1, Table 1). In 31 
patients, 68Ga-PSMA-11-positive metastasis were clearly localized. The mean uptake in the 
submandibular glands was not different between patients with or without 68Ga-PSMA-11-
positive lesions with a SUVmax 23.5±5.2 vs. 23.3±5.1 (p=0.875), respectively. 
 
Prostate cancer 
 
Frozen tissue sections of the apex were analyzed in 9 patients with apical prostate cancer 
confirmed on H&E staining. The area fraction covered by adenocarcinoma on the slides 
ranged from 3% to 33% and included Gleason Scores from 3+3 to 4+4. The corresponding, 
paraffin-embedded tissue stained with an anti-PSMA antibody, indicated PSMA expression 
ranging from low (1+) to strong (3+), covering 70‒100% of the tumor tissue with IRS values 
between 70 - 300 (Table 2).  
In analogy to the IRS score, the signal intensity on ARG images of PCA tissue relative to 
PC-3 PIP tumor xenograft sections showed a heterogeneous pattern with a mean signal 
intensity of 8.5±6.8% and a range between 1.33 – 21.98% (Fig. 2A). The pattern of signal 
intensity on frozen sections corresponded well with the tumor region on H&E histology.  
Also, the in vivo 68Ga-PSMA-11 accumulation determined on PET scans showed a 
heterogeneous SUVmax ranging from 4.4 to 16.0 in the areas of the investigated primary 
prostate adenocarcinoma corresponding to the signal seen on ARG (Table 2, Fig. 3). 
 
Pancreatic tissue 
 
The healthy pancreatic tissue (PANC) was negative for PSMA on IHC in all four cases, 
even in the intercalated ducts (IRS 0; Table 3). The average signal intensity of the ARG 
performed on the pancreatic tissue was minimal in relation to PC-3 PIP tumor xenograft 
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sections (0.1±0.05%, supplemental Fig. S1), as was the case for the 68Ga-PSMA-11  
accumulation on 68Ga-PSMA-11 PET scans that was low as well (SUVmax of 3.1±1.1) (Table 
4). 
 
Salivary glands  
 
Three SMG were atrophic with signs of chronic inflammation, while six glands had a normal 
histology without inflammatory changes. IHC of PSMA expression showed distinct PSMA 
staining intensity (2 to 3+) that were very limited in extent (5% of the tissue) and typically 
confined to the intercalated ducts of normal SMG, yielding an IRS of 10 - 15. Atrophic SMG 
showed a similar pattern, but markedly reduced staining intensity (1+), as well as decreased 
coverage (IRS of 2 - 5 ; Table 3, Fig. 4a-b).  A minor, opaque and inconsistent staining of 
the mucinous glands was regarded as an unspecific artefact.  
The average relative signal intensity on ARG images of SMG was 1.34±0.89%. The three 
atrophic glands showed reduced signal intensity on ARG (0.14±0.1%) compared to the six 
glands with normal histology (1.94±0.32%) (Fig. 2B). Given the fact that most PCA patients 
do not have atrophic salivary glands, further comparison was performed by considering only 
the average uptake of healthy SMG (Table 3).  
In contrast to the low IRS on IHC and the minimal signal intensity on ARG, all SMG on 
68Ga-PSMA-11 PET scans revealed a very strong accumulation of the tracer with a mean 
SUVmax of 23.5±5.2 (range 13.6 – 36.6) (Table 4, Fig. 5). 
 
Correlation between IHC, ARG and PET  
The IRS evaluated by IHC and the ARG intensity showed a significant correlation (R2 = 
0.642, p = 0.009), visualizing the areas of PSMA-positive prostate adenocarcinoma. 
Furthermore, the ARG intensity correlated well with the accumulation of 68Ga-PSMA-11 in 
the apical quadrant of the prostate as determined on PET images (R2 = 0.897, p < 0.001) 
(Fig. 6).  
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In addition, SMG and pancreatic tissue displayed a significant correlation between the low 
IRS (mean SMG 8.7±4.9 and mean PANC 0.0±0.0) and the low ARG signal intensity (mean 
SMG 1.3±0.9% and mean PANC 0.1±0.1%, R2 = 0.739, p<0.001). In vivo accumulation of 
68Ga-PSMA-11 was very strong in SMG, with a mean SUVmax of 23.5±5.2 even surpassing 
the highest uptake detected in primary prostate adenocarcinoma (SUVmax 16.0 in PCA09) 
(Fig. 6). 
Applying a linear fit algorithm for ARG signal intensity and SUVmax, over the 9 PCA cases, 
the following equation would result in (ARG %) = 1.46* (SUVmax) - 3.9. Assuming a similar 
perfusion between SMG tissue and prostate cancer tissue, the same function should be 
applicable for ARG signal intensity and SUVmax on SMG. As a consequence, a mean 68Ga-
PSMA-11 uptake of SUVmax 23.5 determined on PET scans would correspond to an 
average signal intensity of 30% ((1.46*23.5)-3.9) on ARG images. This would, however, be 
a 15-fold increased value as compared to the actual signal intensity of 1.9% determined for 
ARG images of normal SMG in our study. 
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DISCUSSION 
The presented data support a mainly non-PSMA related radioligand uptake in salivary 
glands, in contrast to a significant correlation of PSMA mediated ligand uptake in primary 
PCA. IHC analysis showed a patchy and focal PSMA expression limited to the intercalated 
ducts in SMG, while serous acinar cells and striated ducts did not show PSMA expression.  
On the SMG specimens with chronic sialadenitis and atrophy, the IHC staining pattern was 
similar but overall less intense. These data were confirmed by ARG analysis which showed 
very low signal intensity on SMG tissue. The pancreatic tissue which has a similar histology 
as the SMG did not show any expression of PSMA on IHC and ARG, respectively. As the 
main structural difference between pancreatic tissue and SMG are the striated ducts (25). 
The substantial difference of PSMA radioligand uptake between these tissues may be 
attributed to the striated ducts. However, this would be most likely PSMA-unrelated, as no 
PSMA expression is observed in the striated ducts.  
The consistently high uptake of PSMA radioligands in all seromucous glands of the 
head and neck was also confirmed by Klein Nulent et al. with a retrospective analysis of 30 
patients (26). Together with previous observations of minimal to patchy PSMA expression 
on IHC (2,16,27), this supports the hypothesis that the accumulation of small molecule 
PSMA-targeting radioligands is at least partially non-specific (19).  
This could also explain why the injection of botulinum toxin into the salivary gland, which 
leads to a transient reduction in salivary gland function, reduces the PSMA radioligand 
accumulation up to 64% (28). Some clinicians suggested local cooling to reduce radioligand 
accumulation, however, the reduction of SUVmax by this measure was only 15%, so that 
further investigation is needed before consideration of clinical routine use (29). The 
approach of using inhibitors of PSMA (e.g 2-PMPA), was found more successful in view of 
protecting the kidney from radiation damage (30), rather than the SMG, which was another 
finding supporting the hypothesis that the uptake of PSMA-ligands in salivary glands is 
mostly PSMA-unrelated.  
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The sink effect in patients with high tumor burden is a phenomenon that led to a reduced 
PSMA accumulation in salivary glands (31), however, in the patient selected for this study 
referred for staging or early biochemical reurrence, the tumor burden was not high enough 
to affect the radioactivity uptake in the salivary glands (31).   
A potential limitation of the present study may be the fact that a direct comparison of the 
accumulation of PSMA radioligands in vivo, determined by PET examinations and in vitro 
using ARG of the same specimens for salivary gland and pancreatic tissue is not possible. 
Given the very consistent results for both pancreatic and normal submandibular gland 
tissue regarding ARG and IHC, as well as the consistently high PSMA radioligand 
accumulation in salivary glands of the head and neck and low radioligand uptake in the 
pancreas, we believe that the indirect comparison as presented in this study, is conclusive 
to confirm our hypothesis.  
 
CONCLUSION 
Our data strongly suggest that accumulation of PSMA-targeting radioligands in salivary 
gland tissue is mainly non-specific. Further studies will be necessary to investigate the 
exact mechanism of radioligand accumulation in order to develop new strategies to reduce 
radiotracer uptake in this dose-limiting tissues. This is in particular critical for radionuclide 
therapy using alpha-particle emitters with high linear energy transfer.  
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Tables: 
 
Table 1 Patient characteristics 
  N/mean  (%)/SD 
Submandibular gland: 9  
  Age (years) 59 ±13 
  Previous RTX (yes) 3 33% 
     
Pancreatic tissue: 4  
  Age (years) 66 ±18 
   
PCa-tissue: 9  
  Age (years) 63 ±5.4 
  Prostate cancer (+) 9 100% 
   
PSMA-PET scans: 60  
Age (years) 67.3 ±6.9 
Dose (MBq) 136 ±14.0 
Weight (kg) 84.3 ±10.8 
Number of PCa metastasis 31  
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Table 2 Comparison of the 9 primary prostate tumors (PCa) on histology, autoradiography (ARG) and 
PSMA-PET: Gleason Score (GS), carcinoma covered area of the slide (covered area), predominant IHC 
intensity, percentage of carcinoma showing the predominant intensity, Immunoreactivity score (IRS; 
predominant intensity x percentage of staining); relative signal intensity on ARG, in vivo accumulation of 
68Ga-PSMA-11 (SUVmax/SUVmean). 
 
  
Case: GS 
 
H&E 
PCa-
covered 
area (%) 
PSMA 
IHC 
Intensity 
PSMA 
IHC % of 
Tumor 
PSMA 
IHC IRS 
ARG 
(%) 
PSMA 
SUVmax 
PSMA 
SUVmean 
PCA 01 3+4 13 1 70 70 1.3 4.4 2.9 
PCA 02 4+4 13 2 80 160 2.5 5.3 3.2 
PCA 03 3+3 17 1 80 80 2.6 3.3 2.9 
PCA 04 3+4 28 3 70 210 4.5 4.7 3.1 
PCA 05 3+4 33 2 80 160 6.7 9.2 8.1 
PCA 06 3+4 32 3 100 300 8.8 7.5 5.7 
PCA 07 3+4 3 3 100 300 10.6 12.6 7.5 
PCA 08 4+4 20 3 100 300 17.6 13.9 11.6 
PCA 09 4+4 19 3 100 300 22.0 16 8.8 
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Table 3: Comparison of the 9 salivary gland and 4 pancreatic tissues: histology, PSMA expression 
intensity, percentage of tissue stained and immunoreactivity score (IRS; intensity x % staining) and 
relative signal intensity on ARG. 
  
Case: Histology PSMA 
IHC 
Intensity 
PSMA 
IHC % of 
tissue 
PSMA 
IHC IRS 
ARG 
(%) 
SMG 01 atrophic 1 5 5 0.1 
SMG 02 atrophic 1 2 2 0.2 
SMG 03 atrophic 1 2 2 0.1 
SMG 04 normal 2 5 10 1.9 
SMG 05 normal 3 5 15 1.4 
SMG 06 normal 3 5 15 1.9 
SMG 07 normal 2 5 10 2.2 
SMG 08 normal 2 5 10 1.8 
SMG 09 normal 2 5 10 2.4 
PANC 01 normal 0 0 0 0.0 
PANC 02 normal 0 0 0 0.1 
PANC 03 normal 0 0 0 0.2 
PANC 04 normal 0 0 0 0.1 
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Table 4. Quantification of 68Ga-PSMA-11 accumulated in different tissues based on 
PSMA-PET. (SD = Standard deviation)   
Tissue activity on PSMA PET (SUVmax) 
  N Minimum Maximum Mean SD 
Parotid 60 10.0 30.4 19.8 4.7 
Submandibular 60 13.6 36.6 23.5 5.2 
Lacrimal 60 6.0 25.8 13.8 4.2 
Sublingual 60 3.6 31.0 10.7 4.6 
Tonsils 60 3.0 12.6 7.8 2.1 
Pancreas 60 0.4 5.4 3.1 1.1 
Liver 60 4.1 16.3 8.2 2.6 
Spleen 60 5.0 21.0 11.2 3.9 
PCA-tissue 31 2.7 48.7 15.9 11.8 
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Figures: 
 
 
  
 
Figure 1: Overview of selected patients for tissue collection for autoradiography (ARG) 
and immunohistochemistry (IHC) (submandibular glands (SMG 01-09), pancreas (PANC 
01-04) and primary prostate cancer (PCA 01-09)), as well as PSMA PET quantification, 
including the 9 patients with primary prostate cancer (PCA01-09) and 60 patients 
referred for restaging for the analysis of average uptake on salivary glands, pancreas, 
spleen, liver and prostate cancer metastasis. 
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Figure 2: (A) Autoradiography quantification of signal intensity of human primary prostate 
cancer (PCA) tissue relative to PC-3 PIP (high PSMA expression, set to 100%) and PC-3 flu 
(low PSMA expression) mouse tumor xenograft sections after the application of 177Lu-
PSMA-617. Data shown for unblocked and 2-PMPA-blocked tissue sections. A 
heterogeneous pattern of signal intensity on ARG was observed with a mean of 8.5±6.8%, 
range 1.33 – 21.98% compared to PC-3 PIP tumor tissue. (B) Same ARG qunatification for 
human salivary gland sections. SMG 01-03 with atrophy showed only minimal signal 
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intensity (0.14±0.10%) and SMG 04-09 with normal histology showed low signal intensity 
(1.94±0.32%).  
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Figure 3: Comparison of three selected examples of prostate carcinomas (line by line) 
regarding H&E histology, PSMA IHC, in vitro ARG and in vivo PET. (A) shows encircled 
carcinoma areas in formaline fixed tissue, (B) the respective corresponding PSMA 
immunohistochemisty and (C) the selected encircled carcinoma areas in the fresh frozen 
tissue (scale bar 5 mm). (D) depicts the corresponding in vitro autoradiography with high 
(PCA08, GS 4+4), moderate (PCA04, GS 3+4) and low (PCA03, GS 3+3) normalized 
signal intensity on ARG, whereas (E) shows corresponding axial slice through the apex 
of the prostate on PSMA PET/MR.   
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Figure 4: Comparison of normal and atrophic submandibular salivary gland tissue (SMG 
NOR and ATR), and pancreatic tissue (PANC) regarding H&E histology, PSMA IHC and 
in vivo PET. (A) H&E histology of these three tissue types. (B) Moderate, but focal 
PSMA expression in intercalated ducts (inset, arrow), whereas striated ducts (inset, 
asterisk) are PSMA negative and intercalated ducts of atrophic salivary gland tissue 
show less expression. In pancreatic tissue, no PSMA expression is noted (inset, arrow 
shows negative intercalated duct). Scale bar 5 mm, and 100 µm (insets). (C) depicts in 
vitro ARG with normalized signal intensity for normal and atrophic SMG besides normal 
pancreatic tissue. Scale bar 5 mm. (D) PSMA PET scan of a patient showing high PSMA 
accumulation in the left submandibular gland (orange arrow, SUVmax 33), lower uptake in 
the atrophic right submandibular gland (yellow arrow, SUVmax 11) and only minimal 
uptake in the pancreas (blue arrow, SUVmax 3) (magnification in insets).   
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Figure 5: Box plots illustrating the PSMA-PET activity distribution for 60 consecutive 
patients imaged for PCA recurrence. High accumulation of 68Ga-PSMA-11 60 minutes 
after injection can be measured in the salivary glands of the head and neck area, with a 
maximum in submandibular glands (SMG, orange), followed by parotid gland (PG), 
lacrimal gland (LG) and sublingual gland (SLG). Only minimal uptake was determined in 
the pancreatic tissue (PANC, blue). The average 68Ga-PSMA-11 uptake in the 
submandibular glands was higher compared to the uptake in prostate cancer metastasis 
(PCA, green).  
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Figure 6: Scatter plot with linear regression fit for the quantification of the relative signal 
intensity on ARG images and the corresponding quantification of the in vivo uptake of 
68Ga-PSMA-11 on PET images (SUVmax) for prostate cancer (PCA) specimens (green, 
circle), with a linear regression fit (R2 = 0.897, p < 0.001, y = 1.46*x -3.9). The average 
ARG signal intensity for salivary glands (SMGnor ,1.94%) in relation to the average 
SUVmax on 60 PSMA PET scans (SUVmax 23.5) is shown in orange (square) and the 
ARG signal intensity for the pancreases (PANC; 0.1%) in relation to the average SUVmax 
on 60 PSMA PET scans (SUVmax 3.1) in blue (triangle).  
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SUPPLEMENTAL DATA 
 
METHODS 
Tissue preparation, PSMA immunohistochemistry and evaluation 
Fresh tissue of all types, obtained from the resection specimens immediately after 
surgery, was snap frozen. The remaining tissue was formalin-fixed, paraffin-embedded 
(FFPE) and examined on 2 µm-thick hematoxylin & eosin (H&E) stained sections. 
Immunohistochemical staining was performed on additional 2 µm-thick sections using 
the Ventana Benchmark (Roche Ventana Medical Systems, Inc., Tucson, AZ, USA) 
automated staining system. A primary antibody directed against the extracellular domain 
of PSMA (DAKO, M3620, clone 3E6, 1:25) was used. Detection was performed with 
optiView DAB-kit (Ventana). Slides were counterstained with hematoxylin (Ventana). 
PSMA expression was evaluated using a three-tiered system (1+ weak, 2+ moderate, 3+ 
strong) and the area covered by staining was estimated in the following scale (1%, 2%, 
5%, 10% followed by further 10% steps). Immunoreactivity score (IRS) was calculated 
as following: IRS = IHC expression score multiplied by the area covered (1). The area 
fraction covered by carcinoma on the H&E slides was determined after digitalization of 
the slides (Nanozoomer NDP digital slide scanner C9600-12 by Hamamatsu) using the 
Hamamatsu NDP.view 2.6.8 Software. The Gleason scores and carcinoma areas were 
evaluated on each corresponding slide by an experienced genitourinary pathologist 
(N.J.R.). 
 
177Lu-labeling of PSMA-617 
No-carrier added 177Lu was obtained from Isotope Technologies Garching (ITG GmbH, 
Garching, Germany). Radiolabeling of PSMA-617 was performed at a specific activity of 
100 MBq/nmol. Therefore, the compound was incubated at 95°C with 177LuCl3 and a 
solution of HCl (0.05 M) and Na-acetate (0.5 M) at pH ~ 4 for 10 minutes. Quality control 
was performed by high performance liquid chromatography (HPLC, Merck Hitachi, 
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Darmstadt, Germany) with a C-18 reversed phase column (XTerraTM MS C-18, 5 μm, 15 
cm x 4.6 cm, Waters, Milford, MA, U.S.) and a radio flow detector LB508 (Berthold 
Technologies). The mobile phase consisted of MilliQ water with 0.1% trifluoroacetic acid (A) 
and acetonitrile (B) with a linear gradient from 5% to 80% B over 15 min at a flow rate of 1 
mL/min. The radioligand was used for AR studies at radiochemical yields >98% without 
further purifications. 
 
In vitro PSMA autoradiography 
PSMA-617 (ABX GmbH, Germany) was labeled with no-carrier added 177Lu (ITG GmbH, 
Germany) under standard labeling conditions as previously reported (2). In vitro 
autoradiography was performed on frozen sections of patient tissue  and mouse xenografts 
(PC-3 PIP and PC-3 flu tumor xenografts grown in BALB/c nude mice to serve as positive 
and negative controls, respectively) and immobilized on Superfrost Plus slides (Adhesion 
slides, Thermo Scientific, Germany). The slides with tissue sections were pre-incubated in 
Tris-HCl buffer (170 mM, pH 7.6, with 5 mM MgCl2) containing 0.25% (w/v) bovine serum 
albumin (BSA, Sigma, USA) for 10 min at room temperature. The sections were then 
incubated with a solution of 177Lu-PSMA-617 (1.5 MBq/mL in Tris-HCl buffer containing 1% 
BSA) with or without blocking consisting of 200 μM 2-(Phosphonomethyl)-pentandioic acid 
(2-PMPA, Sigma, USA) for 60 min at room temperature. After removal of the radioligand 
solution, the sections were washed twice for 5 min in cold Tris-HCl buffer (with 0.25% BSA), 
then twice for 5 min in pure Tris-HCl buffer, and finally rinsed with cold distilled water. The 
sections were air-dried followed by exposure to a phosphor imaging screen (Super 
Resolution, Perkin Elmer, USA). The screens were developed using a radiometric phosphor 
imager (Cyclone Plus Storage Phosphor System, Perkin Elmer, USA). The signal intensity 
on the autoradiographic images was quantified by contouring each sample using the 
OptiQuant Acquisition software (Version 5.0, Perkin Elmer, USA). PC-3 PIP and PC-3 flu 
tumor xenograft sections (cells kindly provided by Prof. Dr. Martin Pomper, John Hopkins 
Institutions, Baltimore, USA) were co-exposed and used as a positive or negative control, 
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respectively. The percentage signal intensity relative to the PC-3 PIP section (PC-3 PIP set 
to 100%) was calculated using digital light units per area (mm2). The files generated by the 
OptiQuant Acquisition software were opened and arranged for visual display using Adobe 
Photoshop (Version CS6, Adobe Systems, USA). 
68Ga-PSMA-11 PET/MRI  
All patients underwent a clinical routine whole-body PET/MRI 60 min after injection of 68Ga-
PSMA-11 using a hybrid scanner (SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA). 
For attenuation correction a 3D dual-echo, spoiled gradient recalled echo sequence (LAVA-
FLEX) was acquired, and PET emission scans were recorded in list mode for 2 minutes per 
bed. The MR-based attenuation correction algorithm uses an atlas for the patient’s head 
region. In the other anatomical regions, air, lung and soft tissue were segmented and a 
continuous fat/water-based attenuation correction method was applied(3). Furthermore, a 
high resolution T1-weighted LAVA-FLEX sequence, diffusion weighted images (b values: 0, 
300, 1000) and a T2-weighted fast recovery fast spin echo (FRFSE) sequences in two 
planes were included for the pelvis. To reduce 68Ga-PSMA-11 activity in the bladder, ureters 
and kidneys, furosemide (0.13 mg/kg) was injected intravenously 30 minutes prior to the 
68Ga-PSMA-11 injection, and patients were asked to void the bladder prior to the scan (4). 
 
RESULTS 
In vitro PSMA autoradiography 
use only. 
by UZH Hauptbibliothek / Zentralbibliothek Zurich on February 10, 2019. For personaljnm.snmjournals.org Downloaded from 
 4 
 
 
Fig. S1 Quantification of the signal intensity of human pancreatic tissue relative to PC-3 PIP 
(high PSMA expression, set to 100%) and PC-3 flu (low PSMA expression) tumor xenograft 
sections after the application of 177Lu-PSMA-617. Data shown for unblocked and 2-PMPA-
blocked tissue sections. All PANC tissue sections showed only minimal signal intensity 
(0.1±0.05%) 
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